YWYilin Wang

Yilin Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yilin Wang has a total of 6 co-authors. Here are the top co-authors by number of shared publications:

  • Liren Li

    School of Nursing, Nantong University, 19th Qixiu Road, 226001, Nantong, People's Republic of China.

    2 shared publications
  • C. Dong

    Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, Nantong, China

    1 shared publication
  • Genkai Guo

    Department of Rheumatology, Affiliated Hospital of Nantong University, 20th Xisi Road, Nantong, 226001, Jiangsu Province, People's Republic of China.

    1 shared publication
  • Hongli Wang

    Department of Thyroid and Breast Surgery , Yangzhou , China

    1 shared publication
  • R. Zhao

    Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, Nantong, China

    1 shared publication
  • Z. Gu

    Research Center of Gerontology and Longevity, Affiliated Hospital of Nantong University, Nantong, China

    1 shared publication

Latest Publications

  • Rituximab for connective tissue disease‐associated interstitial lung disease: A systematic review and meta‐analysis

    by Yilin Wang, Liren Li

    Objective: To assess the efficacy of rituximab (RTX) on lung function and the prevalence of adverse events (AEs) in connective tissue disease‐associated interstitial lung disease (CTD‐ILD) by meta‐analysis.Methods: EMBASE, Web of Science, PubMed and ClinicalKey were searched up to July 16, 2021. The lung function (forced vital capacity, FVC% predicted, and diffusing capacity of the lung for carbon monoxide, DLCO% predicted) and prevalence of AEs of RTX in CTD‐ILD were analyzed by meta‐analysis, and 95% confidence interval (CI) was calculated. Subgroup analyses and meta‐regression were used to explore the heterogeneity.Results: We identified 29 studies, including 827 CTD‐ILD patients with a median age of 53.05 years. In observational studies, FVC% (mean difference − 1.24, 95% CI [−2.35, −0.12]; P = .030) and DLCO% (−7.71, [−11.79, −3.63]; P = .014) of CTD‐ILD decreased significantly after RTX treatment. In randomized controlled trials, FVC% of CTD‐ILD decreased after RTX treatment (−5.24, [−9.94, − 0.54]; P = .029), but the difference of DLCO% was not significant (1.15, [−4.33, 6.63]; P = .681). The prevalence of AEs, all‐cause mortality and infections was 29.7% (95% CI [0.17, 0.42]), 11.6% (95% CI [0.08, 0.16]) and 20.9% (95% CI [0.15, 0.27]), respectively.Conclusions: RTX was associated with AEs such as decreased pulmonary function, all‐cause mortality, and infections in CTD‐ILD. Adverse reactions during and after RTX treatment should be carefully monitored. Further prospective studies are needed to compare RTX with other immunosuppressants, antifibrotic drugs or placebos, which can provide therapeutic approaches for CTD‐ILD.


  • Effects of glucocorticoids on osteoporosis in rheumatoid arthritis: a systematic review and meta-analysis

    by Y. Wang, R. Zhao, Z. Gu, C. Dong, G. Guo, L. Li

    We evaluated the effects of glucocorticoids on bone mineral density (BMD), and prevalence of osteoporosis and fracture in rheumatoid arthritis (RA) by meta-analysis. Until June 26, 2019, we conducted a systematic literature search in EMBASE, Web of science, PubMed, and Cochrane Library to obtain BMD and the prevalence of osteoporosis and fracture in glucocorticoid-treated subjects with RA. The BMD of the treatment and control groups were analyzed by meta-analysis (Stata. version 15), and the 95% confidence interval (CI) was calculated. We identified 15 observational studies, including 46,711 RA subjects and 857 healthy controls. The BMD of the lumbar spine (− 0.038 g/cm2; CI, − 0.052, − 0.024) and femoral neck (− 0.017 g/cm2; − 0.030, − 0.003) in RA treated with glucocorticoids were significantly lower than those in RA controls. Compared with healthy control group, the BMD of the lumbar spine (− 0.094 g/cm2; − 0.126, − 0.061) and femoral neck (− 0.097 g/cm2, − 0.109, − 0.085) of RA treated with glucocorticoids decreased more significantly. The prevalence of osteoporosis in whole body, spine, and femur was 38.6% (0.305, 0.466), 32.9% (0.277, 0.381), and 21.7% (0.106, 0.328), respectively. And the prevalence of vertebral fracture was 13.0% (0.058, 0.203). Glucocorticoids may lead to a decline in skeletal health in subjects with RA, especially in vertebral and femoral BMD, compared with normal people or RA without glucocorticoid therapy. Meanwhile, osteoporosis and fractures were also common. Therapeutic measures should be targeted at individuals, which needs further study. Through meta-analysis, we found that glucocorticoids have some negative effects on the bone health of subjects with rheumatoid arthritis. Therefore, when using glucocorticoids to treat rheumatoid arthritis, we should take strategic measures to prevent the decline of bone quality.


  • Open Access

    Effects of Hypothyroidism and Subclinical Hypothyroidism on Sexual Function: A Meta-Analysis of Studies Using the Female Sexual Function Index

    by Yilin Wang, Hongli Wang

    Introduction: Hypothyroidism and subclinical hypothyroidism (SCH) are common metabolic diseases with severe psychological and physiological effects, which may be the risk factors of sexual dysfunction. Aim: The purpose of this study is to explore the influence of hypothyroidism and SCH on female sexual function through systematic literature review. Methods: Until February 2020, systematic searches were conducted on Pubmed, Web of Science, EMBASE, and Clinicalkey to obtain eligible studies to report the mean and standard deviation of Female Sexual Function Index (FSFI) in various fields in women with clinical hypothyroidism, SCH, and healthy controls. In accordance with the results of heterogeneity test, a random effect model or fixed effect model was selected to aggregate the scores of each field. The scores of female patients with hypothyroidism and healthy controls were compared using forest plot. Stata (version 15.1) uses meta-analysis. Main Outcome Measure: Evaluation values of various fields of FSFI in clinical hypothyroidism, SCH, and healthy controls. Results: This study included 7 studies, including 88 women with clinical hypothyroidism, 337 women with SCH, and 2056 healthy controls. Compared with healthy controls, patients with hypothyroidism scored lower in all FSFI dimensions (desire, arousal, lubrication, orgasm, satisfaction, and pain), especially in lubrication. And, only arousal and orgasm decreased in patients with SCH. Hypothyroidism (odds ratio = 3.912, P = .002) rather than SCH (odds ratio = 1.036, P = .886) was a risk factor for female sexual dysfunction. Conclusion: Hypothyroidism does impair female sexual function to varying degrees. SCH has little effect on female sexual function. It is essential to measure and evaluate the thyroid function of women with sexual dysfunction regularly, which can help clinicians improve sexual function and sexual quality of life.